Literature DB >> 7780609

The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer.

N C Gallegos1, C Smales, F J Savage, R M Hembry, P B Boulos.   

Abstract

Studies suggest that the interplay between matrix metalloproteinases (MMPs) and their inhibitors, tissue inhibitor of metalloproteinases (TIMPs), is an important mediator of tumour invasion and metastasis. Using immunohistochemistry, 40 specimens of colorectal cancer were examined for the presence of TIMP-1 and the MMPs, stromelysin, gelatinases A and B and interstitial collagenase. Neither enzyme nor TIMP-1 was detected in histologically normal mucosa. Within malignant tissue, stromelysin and gelatinase A were conspicuously absent in tumour cells but were immunolocalized to the extracellular matrix and for gelatinase A also to peritumoural fibroblast-like cells. Gelatinase B was confined to polymorphonuclear leucocytes. Interstitial collagenase was not identified. TIMP-1 was present in only three of the 40 tumours within the malignant stroma. These observations suggest that the mesenchymal elements of colorectal carcinomas, by acting as a source of MMPs and TIMPs, may modulate tumour invasion.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780609     DOI: 10.1016/s0960-7404(10)80027-1

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  3 in total

1.  Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer.

Authors:  Marcus Langenskiöld; Lena Holmdahl; Peter Falk; Marie-Louise Ivarsson
Journal:  Int J Colorectal Dis       Date:  2004-12-08       Impact factor: 2.571

Review 2.  Matrix metalloproteinase inhibitors in the treatment of cancer.

Authors:  P D Brown
Journal:  Med Oncol       Date:  1997-03       Impact factor: 3.064

3.  Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy.

Authors:  S L Parsons; S A Watson; H M Collins; N R Griffin; P A Clarke; R J Steele
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.